“Why don’t we see a breakthrough in personalized medicine? When you look at the reports in Nature Reviews Drug Discovery from recent years, the bulk of the projects in phase II or III have a biomarker that allows you to select patients who benefit from the drugs. Why don’t we see a shift in the market? What does it take before we see a breakthrough?”
Those hypothetical questions where posed by Peter Høngaard Andersen, managing director of Innovation Fund Denmark, when MedWatch asked him what he would really like to ask other players in the life science industry, as part of our summer series.